A chicken liver-derived polypeptide capable of alleviating alcoholic liver injury, and a preparation method and application thereof
By binding chicken liver-derived peptides to the Keap1 receptor protein, cell inflammation in alcoholic liver injury is reduced, solving the problems of low development efficiency and large side effects of existing chicken liver-derived peptides, and achieving a highly efficient and safe effect in alleviating alcoholic liver injury.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HEFEI UNIV OF TECH
- Filing Date
- 2026-04-17
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies cannot effectively alleviate alcoholic liver damage through food-derived peptides, and traditional liver-protecting drugs have side effects, long development cycles, low efficiency, and difficulty in obtaining highly efficient peptides that target specific pathological processes.
Using chicken liver as raw material, a chicken liver-derived polypeptide with the amino acid sequence Leu-Asp-Phe-Phe was obtained through fermentation and computer high-throughput screening. Combined with solid-phase peptide synthesis, its binding to Keap1 receptor protein was prepared and verified, reducing the level of cell inflammation in alcoholic liver injury, thus preparing a liver-protective polypeptide with a clear structure and high efficiency.
It provides chicken liver-derived peptides with simple structure, high safety and strong biocompatibility, which can enhance the antioxidant capacity of cells in vivo through the Keap1-Nrf2 antioxidant signaling pathway, significantly alleviate alcoholic liver damage, and have potential medical value with no toxicity and no side effects.
Smart Images
Figure CN122404476A_ABST